| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.8M | — | -13.4% |
| SG&A Expense | $3.3M | — | -12.2% |
| Operating Income | -$10.1M | — | +13.1% |
| Income Tax | $0 | — | — |
| Net Income | -$9.8M | — | +10.8% |
| EPS (Basic) | -$1.87 | — | -379.5% |
| EPS (Diluted) | -$1.87 | — | -379.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15.2M | -41.6% | -30.5% |
| Current Assets | $31.7M | -27.4% | -46.1% |
| Total Assets | $38.0M | -24.3% | -43.4% |
| Current Liabilities | $6.9M | -34.8% | +20.1% |
| Total Liabilities | $11.3M | -26.1% | -0.2% |
| Stockholders' Equity | $26.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$13.4M | — | -2.8% |
| Investing Cash Flow | $1.3M | — | -81.7% |
| Financing Cash Flow | $1.2M | — | — |
| -52.2% |